Tag: LimFLow

LimFlow System a ‘cost-effective and high-value alternative’ to traditional therapies

Percutaneous Deep Vein Arterialisation (pDVA) with the LimFlow System offers a cost-effective and high-value alternative to traditional therapies or amputation, according to a recent...

One-year outcomes from PROMISE I US study of LimFlow system published

LimFlow SA recently announced the publication of 12-month data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...

LimFlow receives Japan PMDA approval for clinical study of minimally-invasive technology

LimFlow announced today that the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved its Clinical Trial Notification (CTN) for the Japanese cohort of...

PROMISE I: LimFlow system enables vast majority of patients to avoid...

LimFlow SA has announced the presentation of one-year data from the full patient cohort in its PROMISE I study of the LimFlow percutaneous deep...
deep vein arterialisation

Deep vein arterialisation should be considered in “no option” CLTI patients,...

Midterm results from a study of the largest population of patients with no-option chronic limb-threatening ischaemia (CLTI) treated with percutaneous deep vein arterialisation (pDVA)...

Positive two-year data from ALPS registry of LimFlow system published

LimFlow SA today announced publication of positive two-year data from the ALPS registry of the LimFlow percutaneous deep vein arterialisation (pDVA) system. Results were...

VIVA 2019: LimFlow announces positive six-month data From PROMISE I US...

LimFlow SA today announced the presentation of positive six-month data from the full patient cohort in its PROMISE I early feasibility study of the...

LimFlow completes enrolment in US feasibility study

LimFlow has announced completion of enrolment of the original 10-patient cohort in the US feasibility study of the LimFlow percutaneous deep vein arterialisation system....